Luxembourg, Oct 16, 2024 - (ACN Newswire via SeaPRwire.com) - Moolec Science SA (NASDAQ:MLEC) ("the Company"), a leader in Molecular Farming technology, announced today that the U.S. Department of Agriculture's ("USDA") Animal and Plant Health Inspection Service ("APHIS") has completed its Regulatory Status Review ("RSR") for the Company's genetically engineered ("GE") peas which produce iron through bovine meat proteins. This is the third regulatory clearance from USDA-APHIS achieved by Moolec in an 18-month window, alongside its genetically engineered safflower and soybean for GLASO™ and Piggy Sooy™ products, respectively. Access the official USDA-APHIS publication here."With USDA approval for our GE pea, Moolec has now secured regulatory clearance for all of our key crops in the US: safflower, soybean, and pea," said Gastón Paladini, CEO and Co-Founder of Moolec. "We are proud to be the only Molecular Farming company with three US regulatory approvals and a major commercial contract. This milestone underscores our leadership in the landscape with tangible, science-backed results."Moolec's genetically engineered peas produce high yields of bovine myoglobin, a protein that boosts iron content, making it an ideal alternative for consumers seeking plant-based sources of iron. This product has the potential to revolutionize both the food ingredient market and the $65 billion pea industry by offering a nutritious, iron-rich alternative to traditional meat products.Amit Dhingra, Chief Science Officer for the Company, stated, "The USDA-APHIS Regulatory Status Review for pea marks a significant milestone for Moolec. As the first review for GE pea, it represents a historic development. It validates Moolec's strategic approach and exemplifies our commitment advancing sustainable food production through science and innovation. This approval is a critical step toward enhancing global food supply and meeting the growing demand for innovative, nutritious food solutions for the world."This approval not only showcases Moolec's innovation in Molecular Farming but also highlights the company's commitment to meeting the highest regulatory and safety standards. Moolec has also developed an Identity Preservation Program to ensure sustainable farming practices, promote stewardship for its crops and product quality for partners, clients and consumers alike.According to USDA-APHIS regulation found at 7 CFR part 340, developers may submit a request for a RSR when they believe a GE plant is not subject to the regulation. APHIS reviews the GE plant and considers whether it might pose an increased plant pest risk compared to its non-GE comparator. If APHIS does not identify a greater pest risk relative to the comparator, the GE plant is not subject to this regulation. Regulation 7 CFR part 340 governs the importation, interstate movement, and the environmental release of certain organisms that have been modified or produced by genetic engineering.The USDA-APHIS review process is a critical component of ensuring that genetically engineered crops can be grown safely, and this approval opens the floor for expanded field trials, seed scaling, and eventual commercialization. With increasing interest in science-based ingredients, this approval positions the company to lead a new wave of innovation in the food and agriculture sectors.About Moolec Science SAMoolec is a science-based ingredient company leader in the use of Molecular Farming technology for food and dietary supplementation markets. The Company's mission is to create unique food ingredients by engineering plants with animal protein genes. Its purpose is to redefine the way the world produces animal proteins for the good of the planet. Moolec's technological approach aims to have the cost structure of plant-based solutions with the nutrition and functionality of animal-based ones. Moolec's technology has been under development for more than a decade and is known for pioneering the production of a bovine protein in a crop for the food industry. The Company's product portfolio and pipeline leverage the agronomic efficiency of broadly used target crops like soybean, pea, and safflower to produce oils and proteins. Moolec also has an industrial and commercial R&D capability to complement the company's Molecular Farming technology. Moolec secures a growing international patent portfolio (25+, both granted and pending) for its Molecular Farming technology. The Company is run by a diverse team of PhDs and Food Insiders, and operates in the United States, Europe, and South America. For more information, visit moolecscience.com and ir.moolecscience.com.Forward-Looking StatementsThis publication contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this publication, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this publication will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.Contact InformationPress & Mediacomms@moolecscience.comInvestor Relationsir@moolecscience.comRelated FilesMoolec Has Received USDA Approval For The First Genetically Modified Pea In HistorySOURCE: Moolec Science Copyright 2024 ACN Newswire via SeaPRwire.com.

HONG KONG, Oct 18, 2024 - (ACN Newswire via SeaPRwire.com) - CITIC Telecom International CPC Limited (“CITIC Telecom CPC”), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883) is at the forefront of AI+ innovation era, enabling dual empowerment of technology and data, and fostering a new business model of intelligence and innovation across industries. CITIC Telecom CPC has further unleashed multiple AI+ projects powered by “AI+ Cloud, Network, Security” framework, the integration of AI technology with big data analytics and security capabilities, and vital customer experience, fueling innovative AI+ applications across industries to reshape the Intelligence Operation Journey of enterprises.CITIC Telecom CPC collaborates with partners to co-create AI+ EcosystemFrom “Technology Empowerment”(+AI) to “Data Empowerment” (AI+)AI has become a cornerstone in today’s business landscape. As a leading Global-Local Intelligent DICT Service Partner, CITIC Telecom CPC fully embraces the global digitalization era and proactively deploys the visionary “ICT-MiiND” framework. This framework seamlessly integrates an “innovative” technology stack, the power of algorithms and big data into the ICT service platform, spanning across “Cloud, Network, Security” and bolstering the element of “intelligence” through cutting-edge AI technology and AIOps modules. CITIC Telecom CPC believes in the transformative power of AI+, actively enhances the in-depth integration of AI across various industries, driving innovative projects from focusing on "Big Data Modelling" to "Small-Scale Scenario implementation". CITIC Telecom CPC has not only deployed extensive resources in AI technologies, but also deeply integrated generative AI applications across the full-chain technology modules, evolving from Technology Empowerment (+AI) to Data Empowerment (AI+), ushering in a new era driven by AI algorithms and big data. AI+ covers diverse AI technologies and applications, integrating big data platforms with small-scale scenario models. This approach covers data collection, storage, governance and mining through deep algorithms, machine learning, and intelligent analysis, to develop a range of intelligent applications and AI+ solutions. Tailored to meet enterprise needs, it provides a one-stop service from business transformation to strategic analysis, efficiently fulfilling enterprise requirements.“CITIC Telecom CPC strives to integrate large AI models with diverse AI+ applications in small-scale scenarios, empowering customers to advance intelligent capabilities, unlocking a realm of new possibilities,” said Mr. Brook Wong, CEO of CITIC Telecom CPCMr. Brook Wong, Chief Executive Officer of CITIC Telecom CPC, said, “Striding from +AI to AI+, CITIC Telecom CPC pioneers AI technologies with a steadfast commitment to ‘Innovation Never Stops', continuously optimizes “Cloud, Network, Intelligence, Security” "solutions, and accelerates the development of intelligence-enabled industries. We actively dedicate various resources and collaborate with partners to co-create a prosperous AI+ ecosystem, enrich technical infrastructure, lead our team and the industry towards a generative AI era driven by large language models, AI technologies, data and intelligent analysis. We strive to integrate large AI models with diverse AI+ applications in small-scale scenarios, empowering customers to advance intelligent capabilities, unlocking a realm of new possibilities.”Transformative AI+ Solutions Generate New Driving Force for Data & Security ApplicationsCITIC Telecom CPC stands at the forefront of AI technology. With decades of ICT experience and industry expertise, its data science and innovation teams are propelling AI innovations with cutting-edge algorithms and deep learning techniques, unlocking data value and accumulating a range of generative AI applications for enterprises. The team has developed a series of award-winning and groundbreaking AI+ solutions such as the newly-launched AI Databank and AI Pentest, driving operational efficiency and cost savings for enterprises.AI Databank – Powering Big Data with Fast, Accurate & Actionable Insights on a Single PlatformAI Databank integrates tremendous data from various business systems, collecting a wide array of internal and external information (such as CRM and ERP). Utilizing generative AI technology, enhanced by deep learning and big data training, it enables efficient data management and real-time report generation. Users can interact with the platform to quickly retrieve data and multiple real-time data charts through dialog-based data queries, empowering data-driven decision making. AI Databank also analyzes current and historical data to build forecast models, helping companies in future planning.AI Pentest – Redefining Vulnerability Assessment with Proactive, Secure and Intelligent AutomationCITIC Telecom CPC has successfully led the Security Operations Center (SOC) to enter into a new AI-driven era since the launch of "TrustCSI™ 3.0" cybersecurity solution at the end of last year. The newly-launched AI Pentest plays a key role in the security portfolio. It is a lightweight solution powered by unique AI-driven bypass techniques to expose WAF vulnerabilities, enabling automated routine task scheduling to simplify the assessment of internal network asset and empower enterprises to keep pace with the rapidly changing IT environment. AI Pentest functions as an AI robot cleaner which automatically operates 24x7, helping enterprises identify key vulnerabilities in the network and establish a robust defense against potential threats.CITIC Telecom CPC's AI+ solutions have been implemented in various industries to foster integration of diverse AI+ applicationsAI+ Reshapes Industries with New Scenarios & Business ValuesCITIC Telecom CPC's AI+ solutions have been implemented in various industries to foster integration of diverse AI+ applications, assisting customers in incorporating generative AI technology, deep learning and data applications, empowering digital transformation for enterprises including:- AI+TelecommunicationsCITIC Telecom CPC leverages AI+ innovation capabilities to create a "Network and Information Security Threats Identification Algorithm Model". Leveraging Natural Language Processing (NLP), algorithm models and innovative technical architecture, an "AI+ telecommunications industry" application platform is created. The platform uses large AI security industry models to learn and identify scams as well as the patterns and characteristics of fraudulent calls. A repetitive learning and training cycle, integrated deep learning capability, on a large amount of known scams and fraudulent calls data is conducted to automatically identify new suspicious calls in the network immediately, greatly improving the accuracy of analysis and interception, and generating values for the society.Use case: Developed by CITIC Telecom, “AI+ Digital and Intelligent Cross-border Mobile Network Security Service Platform” project has won multiple distinguished awards in the market. The project utilizes Voice/Signaling/SMS firewall interception to help major telecommunications service providers, mobile service operators and enterprise sector to enable real-time alerts and interception of illegal and fraudulent Voice/SMS messages. The cloud-based platform can be utilized in local and cross-border cross-network scenarios to identify SMS messages from international countries to mainland China and inter-country communications. The solution effectively helps citizens identify registered SMS senders to stop fraudsters from sending scam SMS messages masquerading as other companies or organizations.- AI+ ManufacturingAs the global manufacturing industry is booming rapidly, the integration with different new technologies is accelerating. Powered by AI, enterprises actively deploy multiple AI tools, diverse application scenarios and big data to build an innovative digital and intelligence ecosystem. Industry chain not only enhances production efficiency and quality, but also responds to changes efficiently through digital planning and intelligent analysis, and also devises more precise future operations plans. AI-driven data security solutions provide enterprises with instant responses to security threats,enhanced data and cyber security, secure and intelligent manufacturing environment, elevating intelligent production to a new level.Use case: CITIC Dicastal, the first lighthouse factory in the global aluminum wheel industry, paved the way for its transformation journey with pivotal support from CITIC Telecom CPC and its subsidiary China Entercom in establishing a secure, efficient and fast data highway. This initiative enabled seamless connectivity among its global factories and significantly enhanced its digital and intelligent operational management capabilities. Leveraging its industry expertise, insights and technical knowledge, CITIC Telecom CPC’s Innovation team empowered CITIC Dicastal to overcome networking and security challenges across various application scenarios, including AI-driven manufacturing, process optimization, R&D design, operational decision-making, green and low-carbon initiatives, facilitating to build a “Vertical Industry Big Model of Aluminum Automobile Parts”, enhancing production efficiency and intelligence. CITIC Telecom CPC’s “AI+ Cloud, Network, Security” not only empowers the intelligent enhancement of CITIC Dicastal's entire industry chain but also reinforces its "AI+ Security" capabilities, refines real-time response alerts and develops interconnection across global factories while effectively monitoring information security threats. These initiatives strengthen the cornerstone of information security, forging a new era for the “Lighthouse Factory”. - AI+ AutomobileDemand forecasting is the most important part of the digital and intelligent transformation of an enterprise's supply chain. CITIC Telecom CPC's "Intelligent Order Demand Forecasting Solution" utilizes AI technology to predict complex and fragmented materials, improving the forecasting accuracy of order demand for vehicle models, and dynamically adjusting materials and production capacity planning.Use case: Headquartered in Europe, a world-renowned automobile parts supplier operates in 29 countries and regions, and serves various well-known automobile brands around the world. CITIC Telecom CPC’s "Intelligent Order Forecast Solution" enables customers to increase forecast accuracy to over 80%, optimize supply chain management, and achieve cost reduction and efficiency improvement.- AI+ RetailThe retail industry is undergoing a large-scale implementation of AI applications. CITIC Telecom CPC's “Cloud, Network, Intelligence, Security” integrated platform help enterprises build a secure, efficient and flexible digital infrastructure, enhance network transmission, information security, cloud computing resources and AI platform capabilities through dynamic perception, predictions and intelligent alerts for networks and applications. Harnessing AI technology and data analysis, we facilitate enterprises in expediting their digital transformation. By enhancing traditional workflow designs with scenario templates like customer service management, R&D evaluation, and marketing reports, strategically utilize big data to reinvent business to seize market opportunities.Use case: A world-renowned cosmetics retail brand has been committed to scientific research and innovation for many years. CITIC Telecom CPC's “AI+ Cloud, Network, Security” integrated platform helps to build a secure, efficient and flexible digital infrastructure. The dynamic perception of networks and applications, predictions and intelligent alerts for networks and applications assist the cosmetics retail brand to realize the values of “In Shanghai, For China, and Connect the World" to meet the needs of consumers in mainland China and around the world.To know more information aboutFrom “Technology Empowerment” (+AI) to “Data Empowerment” (AI+),please visit https://www.citictel-cpc.com/en-hk/ict-miindAbout CITIC Telecom CPCWe are CITIC Telecom International CPC Limited (“CITIC Telecom CPC”), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883), serving multinational enterprises the world over by addressing their specific ICT requirements with highly scalable tailored solutions built upon our flagship technology suites, comprising TrueCONNECT™ private network solutions, TrustCSI™ information security solutions, DataHOUSE™ cloud data center solutions, and SmartCLOUD™ cloud computing solutions.With the motto “Innovation Never Stops,” we leverage innovative technologies to boost technology empowerment (+AI). Embracing AI, AR, Big Data, IoT, and other cutting-edge emerging technologies we aim to unlock technical potential. By integrating deep learning and intelligent data analysis technologies, we transform these technologies into data empowerment (AI+) generative applications, reshaping the Intelligence Operation Journey of enterprises.With our Global-Local capabilities, we are committed to providing our customers with one-stop-shop ICT solutions with superior quality. Having a worldwide footprint across nearly 160 countries and regions, including Asia, Europe and America, Africa, the Middle East, and Central Asia, our global network resources connect nearly 170 points of presence (POPs), 60+ SDWAN gateways, 21 Cloud service centers, 30+ data centers, and three dedicated 24x7 Security Operations Centers (SOCs). We are certified with a series of international certifications, including SD-WAN Ready, ISO 9001, 14001, 20000, 27001, and 27017, to ensure our services compliance with international standards and resources for enterprises. We offer local professional services, superior delivery capabilities as well as exceptional customer experience and best practices through our global presence and extensive industry know-how, becoming a leading integrated intelligent ICT service provider to enterprise customers.For more information, please visit www.citictel-cpc.comMedia Contacts:Catherine YuenCITIC Telecom CPC(852) 2170 7536Email: catherine.yuen@citictel-cpc.com Copyright 2024 ACN Newswire via SeaPRwire.com.

香港, 2024年10月18日 - (亚太商讯 via SeaPRwire.com) - 中信国际电讯集团有限公司（「中信国际电讯」，香港交易所股份代号：1883）全资拥有的中信国际电讯(信息技术) 有限公司(「中信国际电讯CPC」) 站在 AI+ 创新发展前沿，实现技术与数据双赋能 ，推动产业链智能化升级新模式。中信国际电讯CPC进一步启动多个人工智能+项目落地，通过智能化升级'智赋云网安'底座；汇聚AI 技术、 大数据分析及信息安全交互能力，深入行业场景，融合智能应用赋能千行百业，重塑企业智能运营之旅。中信国际电讯CPC 携手伙伴共筑AI+ 生态圈从'技术赋能（+AI）'到'数据赋能（AI+）'人工智能(AI)在现今商业环境不可或缺，作为全球化数智通讯服务供应商，中信国际电讯CPC前瞻部署了面向未来的创新策略 'ICT-MiiND / ICT-智赋'。更将'创新'技术、算力算法和大数据元素全栈无缝融合到ICT服务平台中，全面拥抱全球生成式AI时代，夯实智赋云网安。中信国际电讯CPC深信AI+的变革力量，积极投入AI技术和AIOps模块增强'智能'元素，聚焦从'大模型建设'到'小场景落地'能力，提升与各行业深度融合。中信国际电讯CPC不仅部署了丰富的AI技术资源，更通过深度整合生成式AI应用开发的全链条技术模块、实践由技术赋能(+AI )数智化应用模式，演化成数据赋能(AI+)新篇章。AI+不但涵盖多元 AI 技术及应用，更融合大数据平台与小场景模型；从数据收集、存储、治理、挖掘，通过深度算法、机器学习与智能分析，提炼出一系列数智应用场景与AI+ 解决方案。围绕企业需求适配，提供从业务转型到战略解码，再到运营提升的一站式服务，全方位满足企业需求。中信国际电讯CPC行政总裁黄政华先生表示：「中信国际电讯 CPC致力将AI大模型与多元AI+应用小场景应用融合，助力客户创增数智动能，实现更多可能！」中信国际电讯CPC行政总裁黄政华先生表示：「从+AI到AI+新模式，中信国际电讯CPC作为业界AI技术先行者，一直秉持'创新‧不断'研发多元智能技术，持续优化'云网智安'解决方案，提速数智化赋能产业发展。我们积极投放资源，携手伙伴共筑繁荣AI+ 生态圈，丰富技术底座，引领客户及行业走向以大语言模型、AI技术、智能分析及数据驱动的生成式AI年代；致力将AI大模型与多元AI+应用小场景应用融合，助力客户创增数智动能，实现更多可能！」变革性的AI+解决方案 赋予数据及信息安全应用场景新动能中信国际电讯CPC站在AI技术的前沿，凭借二十多年ICT的专业经验和行业知识， 其数据科学和创新团队在人工智能领域持续发力，以创新算法及深度学习技术释放数据价值，更积累了大量生成式AI案例在企业端应用实践，为企业降本增效。一系列屡获殊荣的AI+解决方案中包括最新的AI Databank (智数库)及AI Pentest (渗透测试)。- AI Databank (智数库) - 大数据平台、智能化分析 | 更快、更准、更科学AI Databank (智数库) 通过整合多个系统，收集内外信息 (如客服管理及运营日志等)的海量数据，利用生成式AI技术，经过深度学习与大数据训练，提供数据管理，即时生成报表。并可通过大型语言模型技术驱动的智慧分析功能，让用户以对话式界面与平台互动，快速检索资料及生成各种可视化图表，从而提炼数据驱动的商业价值。此外，更可通过分析当前及历史数据，构建预测模板，助力企业规划未来。- 革新自动AI Pentest (渗透测试) | 更主动、更安全、更智能中信国际电讯CPC自去年底推出的'TrustCSI™ 3.0云网神盾'网络安全解决方案，成功引领安全运作中心(SOC)进入AI驱动的新时代。最新的AI Pentest渗透测试，更在整个方案中发挥关键作用。AI渗透测试是一项轻量级解决方案，采用独特的 AI驱动技术，有效揭示网站应用程序防火墙(WAF)的弱点，并实现自动化的例行任务调度，以简化内部网络资产漏洞评估流程。AI渗透测试如同网络AI扫地机器人，7x24全自动化运作，协助企业找出网络中的关键漏洞，建立强大的主动式防御机制。中信国际电讯CPC的AI+方案落地于千行百业，推动AI+应用向多元场景发展AI+数智化产业新模式 为千行百业创优增值中信国际电讯CPC的AI+方案落地于千行百业，推动AI+应用向多元场景发展，协助产业链将生成式AI技术，深度学习及数据应用全栈融合业务，为企业数字化转型之旅赋能，当中包括：- AI+电讯业中信国际电讯CPC以AI+创新能力打造「网络与信息安全威胁识别算法模型」，凭借自然语言处理，算法模型，与创新技术架构，构建'AI+电讯产业'应用平台，利用人工智能安全行业大模型学习和识别骚扰，以及诈骗电话的模式与特征 ，对大量已知骚扰及诈骗电话资料进行预学习，知识解构和深度训练，自动学习识别网络中即时出现新的骚扰或诈骗电话，大幅提高分析及拦截准确率，为社会缔造价值。用户个案: 中信国际电讯自主研发的'AI+跨境移动通信网络安全管理平台'项目，获得市场上多个重量级奖项。项目通过提供语音／信令/短信防火墙拦截，助力各主要电讯业界、移动服务运营商及企业客户实时预警及拦截非法欺诈语音／短信。平台采用云端架构 ，应用于本地及跨境跨网场景，识别从国际到中国内地、国际与国际之间的通讯，方案有效协助市民识别已获认证的短信发送人，以打击涉及冒充其他公司或机构身份发出短信行骗。- AI+制造业制造业全球发展迅速，与新技术融合的动力与日俱增，在AI的引领下，企业积极综合运用多种AI 工具、多元应用场景和大数据等创新技术，构建革新数智化生态系统。产业链不仅提高生产效率和质量，通过数字规划和智能分析，能高效响应变化，并可更精准做好未来运营规划。加持AI驱动信息安全解决方案，更为企业安全威胁监测提供即时响应，加强数据及信息安全保障，锻造出更安全、更智能的制造环境，助力智能生产领域全面升级。用户个案：中信戴卡是全球铝车轮行业首家'灯塔工厂'，在其数智化建设过程中，中信国际电讯CPC联同子公司中企通信扮演了至关重要的角色，为其搭建了安全、高效、快速的数据高速公路，网络不仅覆盖了广泛的国际区域，还有效地促进了中信戴卡全球各工厂之间的互联互通，并助力其显著提升了数智化运营管理水平。创新团队凭借深厚的行业洞察与技术实力，助力中信戴卡在AI视觉赋能制造、AI赋能工艺优化、AI赋能研发设计、AI赋能运营决策、AI赋能绿色低碳等多个应用场景克服网路和安全等方面的挑战，助力构建'铝制汽车零部件垂直行业大模型'，进一步提高了生产效率和智能化水平。智赋云网安平台不仅为中信戴卡的全产业链智能升级提供了有力保障，更夯实了其'AI+安全'能力，通过自动化威胁监测与高效实时的回应警报，筑牢信息安全底座，锻造'灯塔工厂'新辉煌。- AI+汽车业需求预测是企业供应链数字化、智能化转型布局中的重要一环。中信国际电讯CPC'订单需求智慧预测专案解决方案'，应用AI技术为零散物料供应链提供精准数据分析，提升车型订单需求的预测准确率 ，动态调节物料及产能规划。用户个案：总部位于欧洲的世界知名的汽车零件供应商，业务分布在29个国家地区，服务全球众多知名汽车品牌。中信国际电讯CPC赋能客户打造'订单需求智慧预测专案解决方案'，提升预测准确率达80%以上，优化供应链管理， 实现降本增效。- AI+零售零售业处于人工智能大规模落地的应用水平。中信国际电讯CPC一体化'云网智安'解决方案协助企业构建安全、高效及灵活的数智基础设施，更通过对网络及应用的动态感知、预测及智慧预警，提升网络传输、信息安全、云端运算资源及AI平台的能力。配合AI技术与数据分析助力企业提早数智化部署，在传统工作流设计模式的基础上增加场景模版，如客服管理、研发评审和营销报告等场景，利用大数据规划策略以赢得市场先机。用户个案：国际知名化妆零售品牌多年来致力于科研与创新，凭借中信国际电讯CPC'智赋云网安'综合方案，协助构建安全、高效及灵活的数字基建底座，通过对网络及应用的动态感知、预测及智慧预警，助力实现「在上海、为中国、链全球」的优势价值，满足其中国内地以至世界各地消费者的需求。如欲了解更多有关从'技术赋能（+AI）'到'数据赋能（AI+）'，请浏览：https://www.citictel-cpc.com/sc-hk/ict-miind中信国际电讯CPC简介中信国际电讯（信息技术）有限公司（「中信国际电讯CPC」）是中信国际电讯集团有限公司（香港交易所股份代号：1883）的全资附属公司，公司一直矢志透过先进技术及旗舰解决方案，包括TrueCONNECT™专用网络服务、TrustCSI™信息安全解决方案、DataHOUSE™全球统一云数据中心解决方案及SmartCLOUD™云端运算解决方案，为全球跨国企业提供综合数码解决方案， 满足不同行业的ICT服务需求。凭借「创新‧不断」的服务理念，中信国际电讯CPC积极利用创新技术，提炼'技术赋能'，将人工智能、扩增实境、大数据，物联网和其他尖端新兴技术，融合深度学习及智能数据分析技术，转化为'数据赋能'生成式AI+应用，重塑企业智能营运之旅。中信国际电讯CPC以「服务在地，连接全球」优势，承诺为客户提供优质的一站式ICT服务。全球化网络资源连接近170个服务据点、60多个SDWAN 网关；21个云服务中心、30多个数据中心及3个全天候运作的安全运作中心，服务遍布约160个国家和地区，无缝连接亚洲、欧美、非洲、中东以及中亚等地区 。透过全球化服务布局，多年不断深耕各个行业与领域经验，一系列国际标准服务认证（SD-WAN Ready, ISO 9001、14001、20000、27001 及27017），确保为企业提供国际化标准及服务资源，专业的在地服务及交付能力，同时，优质的客户体验和服务质量，成为领先的综合信息智能化服务供应商。请浏览www.citictel-cpc.com 获取更多资讯。传媒查询：Catherine Yuen中信国际电讯CPC(852) 2170 7536电邮：catherine.yuen@citictel-cpc.com Copyright 2024 亚太商讯 via SeaPRwire.com.

ISTANBUL, October 18, 2024 - (ACN Newswire via SeaPRwire.com) - The 15th Turkish-Arab Economic Forum (TAFF 2024), aimed at deepening relations between Turkiye and the Gulf countries and defining joint strategies for the region, took place yesterday in Istanbul.The Forum saw the attendance of many key figures from the Gulf countries, including Kuwait's Minister of Finance Noora Suleiman Salem Al-Fassam, Iraq's Minister of Finance Taif Sami Mohammed, Egypt's Deputy Minister of Finance Ahmed Kouchouk, Tunisia's Minister of Economy and Planning Samir Abdelhafidh, Libya's Minister of Finance Dr Kalid Al-Mabrouk, President of the Turkish Investment Fund Baghdad Amreyev, Secretary General of the Egyptian Federation of Arab Chambers Dr Khaled Hanafy, Regional Director of the Saudi International Finance Corporation Fawaz Bilbeisi, Director of the World Bank GCC Cooperation Safaa El Tayeb El-Kogali, Partner at the UK's DWF Solomon Ebere, Board Member of the Qatar Chamber Mohamed Bin Ahmed Al Obaidly, and Vice President of International Business Development of the United Arab Emirates Khalid Al Marzooqi.Turkiye's Minister of Treasury and Finance Mehmet Simsek evaluated global and regional strategies.In his speech at the 15th Turkish-Arab Economic Forum, Minister of Treasury and Finance Mehmet Simsek highlighted the decline in inflation and the slowdown in monetary policies. He emphasized that global trade will continue in November, pointing out that while there are challenges, there are also opportunities in this process. Mehmet Simsek further noted that he expects an increase in cooperation across various sectors, emphasizing that partnerships in energy, manufacturing, technology, and machinery are crucial for realizing the region's potential and he expressed his support for diversification strategies.Dr. Erkan Kork stated that Turkiye and the Gulf countries could build a shared future.Speaking at the 15th Turkish-Arab Economic Forum, Dr. Erkan Kork, Chairman of the Board of BankPozitif, highlighted that the participating countries share the same geography, history, and values, and emphasized that joint steps would be stronger and more effective. He noted that building a shared future with the available know-how, technology, and investments is vital for unlocking the region's potential.BankPozitif Chairman Dr Erkan Kork at the 15th Turkish Arab Economic ForumExpressing pride in Turkiye's positioning as a fintech hub, Dr Erkan Kork predicted that Turkiye would play a leading role on the global stage in various fields in the near future. He also stressed the importance of forums, fairs and events like this for fostering relationships between the business world and governments of different countries.In his speech, Dr Erkan Kork pointed out that Turkiye is in a very strong position in terms of innovation and information technology, noting that while processing times in many sectors in Europe are long, they are much shorter in Turkiye. Dr. Erkan Kork also highlighted Turkiye's high level of competitiveness in recent years.At the forum, which had a high participation rate, Fatih Karahan, Governor of the Central Bank of the Republic of Turkiye, Burak Dagloglu, Member of the Board of Directors of the Turkiye Wealth Fund, and Rfat Hisarckloglu, President of the Union of Chambers and Commodity Exchanges of Turkiye, were also among the speakers.Source: BankPozitif, https://www.bankpozitif.com.trSait Inanc, +90533 722 49 69, info@bankpozitif.com.tr* This press release is issued through EuropeNewswire.Net (www.europenewswire.net) and distributed by EmailWire (www.emailwire.com) – the gloabal newswire that provide Press Release Distribution with Guaranteed Results™. Copyright 2024 ACN Newswire via SeaPRwire.com.

SHENZHEN, CHINA, Oct 18, 2024 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 18 October, the first batch of prescriptions of ruxolitinib phosphate cream (the “ruxolitinib cream” or the “Product”) for qualified vitiligo patients were issued in the Greater Bay Area, at Zhongshan Chen Xinghai Hospital of Integrated Traditional Chinese and Western Medicine, Foshan Fosun Chancheng Hospital, and Dongguan Songshan Lake Tungwah Hospital. The Product’s new drug application (NDA) was approved by the Pharmaceutical Administration Bureau (ISAF) of Macau on 11 April 2024, and subsequently the Product was approved by the Guangdong Provincial Medical Products Administration on August 19 through the "Hong Kong and Macau Medicine and Equipment Connect" policy, which officially introduced ruxolitinib cream for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age, providing a novel treatment option for patients with relevant indication into designated medical institutions in the Mainland of Greater Bay Area.In addition, on 24 September, the NDA for vitiligo indication of ruxolitinib cream has been accepted by the National Medical Products Administration of China (NMPA). In accordance with the relevant regulations of the drug real-world data application pilot program in the Hainan Boao Lecheng International Medical Tourism Pilot Zone (the “Pilot Zone”), CMS has conducted a real-world study on ruxolitinib cream in China. The results have shown positive efficacy, which is consistent with the key outcomes of global pivotal clinical studies. All secondary efficacy endpoints showed a trend of benefit consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with longer treatment duration. Meanwhile, through the safety monitoring data of the Pilot Zone, no new safety events have been identified. Adverse events mostly had severity levels of grade 1 or 2. No adverse event (AE) leading to discontinuation or withdrawal, and no serious adverse event (SAE) related to the study drug occurred.If the Product is successfully approved for marketing in Mainland China, it will be the first prescription drug approved by NMPA for repigmentation in vitiligo, bringing this novel treatment hopes for Chinese vitiligo patients.Furthermore, on 12 August 2023, the Product was approved by Hainan Medical Products Administration for Urgent Clinical Import, and officially became available to applicable patients in the Pilot Zone on August 18, for the topical treatment of non-segmental vitiligo in adults and adolescents aged 12 and above with facial involvement. Benefiting from the Early and Pilot Implementation Policy granted by the state to Hainan Free Trade Port and the Pilot Zone, patients with vitiligo in China can apply for the Product in Boao Super Hospital first and receive treatment from the expert team. As of 30 June 2024, more than 3,200 patients have been treated with ruxolitinib cream in Boao Super Hospital.CMS has always been patient-oriented and innovation-driven based on clinical needs, continuously striving to improve drug accessibility. Benefited from the "Hong Kong and Macau Medicine and Equipment Connect" policy, ruxolitinib cream was approved for use in the Greater Bay Area and completed its first batch of prescriptions, shortening the time difference for Chinese vitiligo patients to use innovative drug and benefiting more domestic patients. Looking forward to the future, the Group will continuously strive to meet the unmet needs of Chinese patients, continuously explore novel drugs with international quality, and efficiently promote products’ clinical development and commercialization, so as to bring more quality pharmaceutical products through differentiated innovation-breakthrough, to safeguard the health and life-quality of patients.About ruxolitinib creamRuxolitinib cream (Opzelura), a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, is approved by the U.S. Food & Drug Administration for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older. As of now, it is the first and only treatment for repigmentation approved for use in the United States[1]. Ruxolitinib cream (Opzelura) is also approved in the U.S. for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable[2]. In Europe, ruxolitinib cream (Opzelura) is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3].On 2 December 2022, the Group through a subsidiary of the Company, a dermatology medical aesthetic company (“CMS Skinhealth”) entered into a Collaboration and License Agreement (the “License Agreement”) with Incyte for topical formulations of ruxolitinib for the treatment of autoimmune and inflammatory dermatology diseases. In accordance with the License Agreement, the Group through CMS Skinhealth received an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (Indonesia, Philippines, Vietnam, Thailand, Myanmar, Malaysia, Cambodia, Laos, Singapore, Timor-Leste and Brunei Darussalam) (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The License Agreement commenced on its effective date and has a royalty term of ten years from the date of the commercial sale of the Product in the Territory (the “Royalty Term”). Upon the expiration of the Royalty Term, the License Agreement may be renewed for a period of ten years thereafter (the “Initial Extended Royalty Term”) as per certain conditions defined in the License Agreement. Upon the expiration of the Initial Extended Royalty Term, the License Agreement may be extended for a period otherwise agreed by both sides as per certain conditions defined in the License Agreement.Incyte has worldwide rights for the development and commercialization of the Product, marketed in the United States and Europe as Opzelura®. Opzelura and the Opzelura logo are registered trademarks of Incyte.About vitiligoVitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 14 million vitiligo patients in China[4]. Non-segmental vitiligo patients account for approximately 85% of them. Topical corticosteroids (TCS) and calcineurin inhibitors (CI) are used off-label for non-segmental vitiligo, however, these therapies have clinical deficiencies with long-term adverse reactions of long-term treatment or limited efficacy[5,6].About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a "bridgehead" for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.Reference:1. Drug approval information can be found on the FDA official website, as follows: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older2. Drug approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream3. Drug approval information can be found on the EMA official website, as follows: https://www.ema.europa.eu/en/medicines/human/EPAR/opzelura4. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84. doi:10.1016/S0140-6736(14)60763-75. Consensus on the diagnosis and treatment of vitiligo (2021 version)6. Kubelis-López DE, Zapata-Salazar NA, Said-Fernández SL, Sánchez-Domínguez CN, Salinas-Santander MA, Martínez-Rodríguez HG, Vázquez-Martínez OT, Wollina U, Lotti T, Ocampo-Candiani J. Updates and new medical treatments for vitiligo (Review). Exp Ther Med. 2021 Aug;22(2):797. doi: 10.3892/etm.2021.10229. Epub 2021 May 25. PMID: 34093753; PMCID: PMC8170669.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactChina Medical System Holdings Ltd.CMS Investor RelationsWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2024 ACN Newswire via SeaPRwire.com.

深圳, 2024年10月18日 - (亚太商讯 via SeaPRwire.com) - 康哲药业控股有限公司（"康哲药业"）欣然宣布，磷酸芦可替尼乳膏（"芦可替尼乳膏"或"产品"）在中山陈星海中西医结合医院、佛山复星禅诚医院、以及东莞松山湖东华医院为符合条件的白癜风患者开出大湾区首批处方。产品于2024年4月11日获得澳门政府药物监督管理局（ISAF）批准新药上市申请，随后通过"港澳药械通"政策，并于8月19日获得广东省药品监督管理局批准，正式落地粤港澳大湾区内地指定医疗机构，用于12岁及以上青少年和成人患者伴面部受累的非节段型白癜风的治疗，为相关适应症患者提供了全新治疗选择。此外，芦可替尼乳膏白癜风适应症新药上市许可申请已于9月24日获得中国国家药品监督管理局（NMPA）受理。根据海南博鳌乐城国际医疗旅游先行区药品真实世界数据应用试点程序有关规定，芦可替尼乳膏在中国开展真实世界研究，疗效积极，与境外关键临床研究结果一致。所有的次要疗效指标均显示出与主要疗效指标一致的获益趋势，且治疗时间越长，患者的白癜风治疗效果持续改善。同时利用了乐城先行区安全监测数据，未发现新的安全性事件。不良反应的严重程度大部分均为1级或2级，未发生导致停药或退出的不良事件（AE），未发生研究药物相关的严重不良事件（SAE）。若产品于中国大陆获批上市，其有望成为首个经NMPA批准用于白癜风复色的处方药，将为中国广大白癜风患者带来治疗新曙光。除上述进展外，产品此前于2023年8月12日获得海南省药监局批准临床急需进口，并于8月18日正式落地海南博鳌乐城国际医疗旅游先行区，用于12岁及以上青少年和成人患者伴面部受累的非节段型白癜风的局部治疗。受益于国家赋予海南自由贸易港、博鳌乐城国际医疗旅游先行区"先行先试"特许政策，中国白癜风患者可在博鳌超级医院先行申请使用产品并接受专家团队的治疗。截至2024年6月30日，已有超3,200例患者在博鳌超级医院使用芦可替尼乳膏进行治疗。康哲药业始终以患者为中心，以临床需求驱动创新，为提升药物可及性而持续努力。本次芦可替尼乳膏得益于"港澳药械通"政策支持，先行获批引入大湾区，并完成首批处方落地，缩短了中国白癜风患者使用创新药的用药时差，让更多国内白癜风患者获益。展望未来，康哲药业将继续为满足中国患者未尽之需而奋进，持续挖掘国际品质的新药、好药，高效推动产品临床开发和商业化发展，以差异化的创新突破为病患带来更多优质的医药产品，为守护患者健康生活和生命质量贡献力量。关于芦可替尼乳膏芦可替尼乳膏（Opzelura），为Incyte的JAK1/JAK2选择性抑制剂芦可替尼的创新乳膏制剂，已获得美国食品和药物管理局（FDA）批准用于12岁及以上非节段型白癜风患者的局部治疗。截至目前，芦可替尼乳膏是首个也是唯一一种在美国获批使用的白癜风复色产品[1]。此外，产品在美国获批用于传统外用处方疗法不可取或不能充分控制病情之12岁及以上非免疫功能低下的轻中度AD患者的局部短期和非持续性慢性治疗[2]。产品也于欧洲获批用于12岁及以上青少年及成人患者伴面部受累的非节段型白癜风的治疗[3]。康哲药业于2022年12月2日，通过其附属公司-康哲美丽与Incyte就用于治疗自身免疫性炎症皮肤病的芦可替尼乳膏制剂订立合作和许可协议（"许可协议"）。根据该等许可协议，康哲药业通过康哲美丽获得在中国大陆、香港特别行政区、澳门特别行政区、台湾地区及东南亚十一国（印尼、菲律宾、越南、泰国、缅甸、马来西亚、柬埔寨、老挝、新加坡、东帝汶以及文莱）（"区域"）开发、注册及商业化产品的独家许可权利，以及在区域内生产产品的非独家许可权利。许可协议期限开始于许可协议生效日，自产品在区域内首次商业化销售之日起拥有十年的授权期限（"授权期限"）。授权期限届满后，根据许可协议约定的特定条件，许可协议期限可延长十年（"初始延展授权期限"）。初始延展授权期限届满后，根据许可协议约定的特定条件，双方可另行协商许可协议的延长期限。Incyte拥有产品的全球开发和商业化权利，产品在美国及欧洲以Opzelura的名称销售。Opzelura及其logo为Incyte的注册商标。关于白癜风白癜风是一种慢性自身免疫性疾病，其特征是皮肤色素脱失，其发病原因为产生色素的细胞即黑素细胞的缺失。据估算，中国白癜风患者约1,400万[4]。白癜风患者中约85%为非节段型白癜风。外用皮质类固醇（TCS）及钙调神经磷酸酶抑制剂（CI）均为非节段型白癜风的标签外用药，然而，这些现有外用药物疗法有长期用药的不良反应或疗效有限的临床痛点[5、6]。关于康哲药业康哲药业是一家链接医药创新与商业化，把控产品全生命周期管理的开放式平台型企业，致力于提供有竞争力的产品和服务，满足尚未满足的医疗需求。康哲药业专注于全球首创（FIC）及同类最优（BIC）的创新产品，并高效推进创新产品临床研究开发和商业化进程，赋能科研成果向诊疗实践的持续转化，造福患者。康哲药业聚焦专科领域，拥有被验证的商业化能力，广泛的渠道覆盖和多疾病领域专家资源，核心在售产品已获领先的学术与市场地位。康哲药业围绕优势专科领域不断纵深发展，以巩固心脑血管/消化业务竞争力，并将皮肤医美、眼科业务独立运营，培育专科小领域的大龙头，提升专科规模效率。同时业务版图拓展至东南亚市场，着力成为全球药企进军东南亚市场的"桥头堡"，助力康哲药业高质量持续健康发展。参考文献/资料：1.FDA批准信息可在FDA官网查询，网址：https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older2.FDA批准信息可在incyte官网查询，网址：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream3.EMA批准信息可在EMA官网查询，网址：https://www.ema.europa.eu/en/medicines/human/EPAR/opzelura4.Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84. doi:10.1016/S0140-6736(14)60763-75.《白癜风诊疗共识（2021版）》6.Kubelis-Lopez DE,Zapata-Salazar NA,Said-Fernandez SL, Sanchez-Dominguez CN,Salinas-Santander MA,Martinez-Rodriguez HG,Vazquez-Martinez OT,Wollina U,Lotti T,Ocampo-Candiani J. Updates and new medical treatments for vitiligo (Review). Exp Ther Med. 2021 Aug;22(2):797. doi: 10.3892/etm.2021.10229. Epub 2021 May 25. PMID: 34093753; PMCID: PMC8170669.康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及康哲药业的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。康哲药业并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，康哲药业对该等第三方声明及预测不承担责任。 Copyright 2024 亚太商讯 via SeaPRwire.com.